Dekker A W, Rozenberg-Arska M, Sixma J J, Verhoef J
Ann Intern Med. 1981 Nov;95(5):555-9. doi: 10.7326/0003-4819-95-5-555.
Fifty-two patients with nonlymphocytic leukaemia were studied during remission induction treatment in a randomized trial to ascertain the effect of prophylactic oral trimethoprim-sulfamethoxazole on infection and fever rate. A decrease in the total number of acquired infections was found (16 infections in the group given trimethoprim-sulfamethoxazole versus 31 in the control group, p less than 0.01). The number of patients without any infection in the trimethoprim-sulfamethoxazole group was 13 compared to only three in the control group (p less than 0.01). Patients in the trimethoprim-sulfamethoxazole group needed parenteral antibiotics during 33% of the days they were granulocytopenic compared to 61% of these days for patients in the control group. However, six of nine bacteriologically documented infections in the trimethoprim-sulfamethoxazole group were caused by resistant microorganisms compared to two out of 20 in the control group.
在一项随机试验中，对52例非淋巴细胞白血病患者在缓解诱导治疗期间进行了研究，以确定预防性口服甲氧苄啶-磺胺甲恶唑对感染和发热率的影响。发现获得性感染总数有所减少（给予甲氧苄啶-磺胺甲恶唑的组有16例感染，而对照组有31例感染，p<0.01）。甲氧苄啶-磺胺甲恶唑组无任何感染的患者有13例，而对照组仅有3例（p<0.01）。甲氧苄啶-磺胺甲恶唑组的患者在粒细胞缺乏的天数中有33%需要静脉用抗生素，而对照组患者在这些天数中有61%需要。然而，甲氧苄啶-磺胺甲恶唑组9例细菌学证实的感染中有6例是由耐药微生物引起的，而对照组20例中有2例。
